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Few biopharmaceutical preparations developed from biologicals are available for tissue regeneration and scar management. When
developing biological treatments with cellular therapy, selection of cell types and establishment of consistent cell banks are crucial
steps in whole-cell bioprocessing. Various cell types have been used in treatment of wounds to reduce scar to date including
autolog and allogenic skin cells, platelets, placenta, and amniotic extracts. Experience with fetal cells show that they may provide
an interesting cell choice due to facility of outscaling and known properties for wound healing without scar. Differential gene
profiling has helped to point to potential indicators of repair which include cell adhesion, extracellular matrix, cytokines, growth
factors, and development. Safety has been evidenced in Phase I and II clinical fetal cell use for burn and wound treatments with
different cell delivery systems. We present herein that fetal cells present technical and therapeutic advantages compared to other
cell types for effective cell-based therapy for wound and scar management.
1. Introduction
Cell-based therapies are penetrating gently into routine med-
ical care and especially for wound management of skin. They
offer the promise of repairing and/or replacing damaged
tissue and restoring lost functionality, because ideally, they
provide all of the factors necessary for wound healing. Several
cell types and tissues have been proposed as starting material
including autologous cells, adult stem cells including those
derived from bone marrow, and adipose tissue, fetal cells,
embryonic stem cells, platelets, and tissues from placental
and amniotic fluid. These cell types are used for biological
preparations in processing vaccines and medicinal, veterinar-
y, and tissue engineering products [1–41]. As the literature
and information is vast on cell-based therapies, this paper
will concentrate on fetal cells as the choice in wound and scar
management. Firstly, we will define differences between stem,
and mesenchymal and fetal cells, as the literature is confusing
with these terminologies, followed by a short review of fetal
wound healing and associated processes. Importantly, cell
choice and the technical specifications to outscale, stability,
safety, and delivery are the major hurdles for develop-
ment of biologicals for better wound treatments and scar
management. Fetal skin cells present biological, technical,
and therapeutic advantages lending towards possible routine
cellular-based therapy for wound and scar management. All
of these aspects will be addressed in the description of how
dedicated fetal skin cell banks can be developed, potential
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Figure 1: Cellular source and development stage with advantages and disadvantages.
delivery systems, and cellular mechanisms of repair with
gene profile differences between fetal and young skin cells
to illustrate biological families implicated in wound healing.
Finally, the capacity of this cell type in wound and scar
management is illustrated and summarized from Phase I and
II clinical safety studies in humans.
1.1. Cellular Sources as Therapeutic Agents: Terminology Clar-
ification, Technical Requirements, and Cell Banking. There
is some confusion between the terminology and potential
of embryonic, fetal, and adult stem cells. These cells are
referred to in the literature as embryonic stem cells, fetal
cells, and mesenchymal stem cells, respectively. However,
more frequently, all of these cell types are referred to as
simply stem cells, neglecting all of the legal and technical
aspects associated with each specific cell type. To illustrate
these differences, Figure 1 lists the major cell sources used in
developing therapeutic applications showing that some cell
choices are more adaptable to cellular therapy in patients.
This adaptability is highly associated with technical facility
of expanding and selecting cell populations needed. Tissue
choices from animal and human at all ages of development
can be evaluated with advantages and disadvantages for each
final cell type (Figure 1). In legal aspects, the term “embryo”
denotes the earliest stages following fertilization of an ovum
by a sperm. Zygote would include early stage cleavage
embryos produced by cell division up to 50–60 cell stage
(each cell which is a blastomere) and the blastocyte for the 60
cell stage to the point of implantation at about 2 weeks after-
fertilization. “Embryonic stem cells” (ES) are developed from
preimplantation embryos from the inner-cell mass before
the first 2 weeks of development. These cells are frequently
obtained from extra embryos developed by “in vitro” fer-
tilization techniques to aid couples for fertility purposes.
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Because these particular cells have created quite an ethical
debate, other researchers have begun using “fetal embryonic
cells” derived from voluntary interruption of pregnancy
between 5 and 8 weeks. Cell lines are normally developed
from the genital ridge of the fetus. As this tissue is considered
as an organ donation in most countries, it bypasses the major
problems that have been raised by embryonic stem cells.
Most fetal cell research is developed from specific tissues such
as skin, muscle bone, or cartilage at the latter end of the first
trimester (11–14 weeks) following voluntary interruption
of pregnancies. Cell lines at this stage are tissue specific,
and therefore, “fetal cells” are differentiated with specific
functions. Fetal cells are derived from a legal organ donation
when the mother donor ensures informed consent, provided
that the tissue is a donation and not paid for and that there is
no change in timing or method of pregnancy interruption for
the sake of research. As fetal cells are from organ donations
and under transplantation medicine, they are also routinely
included in the terminology as adult stem cells.
Adult stem cells can be established from most tissues
of the body, and the most frequently isolated ones come
from bone marrow and adipose tissues of young and adult
individuals and are referred to as “mesenchymal stem cells”
(MSCs).
Each of the cell types mentioned in Figure 1 have
different technical requirements for producing appropriate
cells that could be used as therapeutic agents.
Embryonic stem cells that are isolated from early-stage
embryo present the particularity of being pluripotent and
have an advantage over those cells from adult mesenchy-
mal stem cells, which can differentiate only into a restricted
number of cell lineages. However, cultures of these stem cell
types are technically very demanding, because the amount
of tissue to begin is very low for embryonic stem cells and
the isolation of mesenchymal stem cells from the tissue mass
is difficult (only 1 stem cell for every 104−5 cells in total
adult tissue). Maintenance and expansion of stem cells in an
undifferentiated state require the addition of many specific
growth factors [28, 29], and so far, culture of embryonic
stem cells and some mesenchymal stem cells are not possible
without feeder layers which is in some part responsible for
the inconsistent colony cell growth [29]. The necessity to use
many exogenous growth factors as well as feeder layers to
differentiate into specific cellular lineages are limiting factors
for the scaleup of stem cell cultures for clinical applications.
There are other major issues with these stem cell types for
security as the cells can dedifferentiate once placed into an
in vivo environment and even develop into tumors. Many
techniques involving cell cloning or encapsulation would be
necessary for assuring delivery of correct cell populations.
Unlike stem cells, fetal cells are differentiated cells with
high expansion, regeneration, and low immunogenic prop-
erties [10, 12]. As the fetal cells are already differentiated and
do not need to be directed or altered, the vast number of
additional growth factors normally necessary are not needed
for cell culture and expansion, and these cells are not known
to dedifferentiate once placed into the in vivo environment
[7–9, 12].
Establishment of cell banks is a crucial step in the process
of many vaccines, medicinal products, or tissue-engineering
products, and therefore, the choice of cell type is extremely
important for technical and security reasons. A “cell bank”
is the stocked product of consistent cell cultures that are
frozen into small vials that withstand long-term freezing in
liquid nitrogen (−165◦C). The initial cell bank is frequently
termed the master cell bank (MCB) from which each vial can
derive a working cell bank (WCB). Whole cell bioprocessing
and adaptable procedures to good manufacturing processes
(GMPs) make it possible to develop extensive MCB and
WCB to facilitate thorough testing of the cells. Once MCBs
are accomplished, WCB can be produced to establish indi-
vidual batches of treatments for high numbers of patients.
Further, these cell banks can be tested completely for safety
regarding sterility, pathogens and adventitious agents, and
tumorigenicity.
Historically, fetal cells have been used in cell banking
procedures for medicinal products for many years already.
Already in the 1930s, medical doctors and scientists have
used tissue from voluntary pregnancy interruptions not only
for understanding cell biology but also an important entity
in the development of vaccines by using defined tissue-
derived cell lines. The Nobel Prize for Medicine in 1954
was awarded to American immunologists who developed the
polio vaccine based on cultures of human fetal cells. Since
this time, many other necessary vaccines (rubella, chicken
pox, hepatitis A, etc.) have been developed with the use of
fetal cell lines including two primary human diploid cell
lines which were originally prepared in the 1960s. The first
cell line, WI-38 (Wistar Institute 38), was developed by
Leonard Hayfleck in 1964 from fetal tissue from a voluntary
pregnancy interruption and later given the ATCC (American
Type Culture Collection) number of CCL-75. This cell line
was used for the historical production of vaccine RA 27/3
against Rubella.
1.2. Fetal WoundHealing. Considerable interest and research
have been dedicated to the understanding of wound healing
and the associated process. Whereas adult cutaneous wounds
heal more slowly and with scar formation to restore tissue
integrity, fetal skin, in utero, is observed to have rapid and
scarless tissue repair characterized by regeneration of an or-
ganized dermis with normal appendages and by a relative
lack of inflammation [42–45]. Fundamental differences be-
tween fetal and adult skin and the fetal and adult skin wound
environment may be important in inducing efficient tissue
repair.
Molecular analysis of wound healing has largely been de-
voted to cytokines and most particularly those of the trans-
forming growth factor (TGF) family and their role in manip-
ulating cutaneous wound healing and scar formation [46]. It
has been suggested that scarless wound healing in fetal skin
at early gestation is a result of the unique cytokine or growth
factor profile [3, 45]. Of these, transforming growth factor-
beta (TGF-β) has been most widely studied as it is implicated
in the transition between scarless healing and repair with scar
formation [47].
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Three highly homologous TGF-β isoforms are known in
humans: β1, β2, and β3 [46]. Each form has been found by
immunohistochemistry in unwounded fetal skin. However,
low levels of TGF-β1 and high levels of TGF-β3 are expressed
at gestational ages associated with scarless repair [3, 45].
Exogenous application of TGF-β1 to normally scarless
fetal wounds resulted in scar formation with an adult-like in-
flammatory response observed [47]. The profibrotic nature
of TGF-β1, and possibly TGF-β2, was confirmed in wounds
of adult rats, since neutralizing TGF-β1 and β2 with antibod-
ies partially reduced the amount of scarring [48]. However,
antifibrotic properties can be seen with the isoform TGF-β3
as injection, or application of this isoform showed reduced
scarring and inflammation in adult wounds [48, 49]. When
using a rabbit hypertrophic scar model, TGF-β3 was con-
firmed to show increased properties in wound healing but
not scar reduction [50]. It has been suggested that the relative
proportion of TGF-β isoforms, and not the absolute con-
centration of any one isoform determines the wound repair
outcome [3, 45–47].
TGF-β2 has been shown to be significantly higher in fetal
skin dermal fibroblasts than in foreskin tissue fibroblasts but
no major differences with TGF-β1 and TGF-β3 [11]. When
looking at expression of the three isoforms in five different
fetal skin cell lines, it was observed that TGF-β1 gene expres-
sion is much higher than that of TGF-β3. Importantly, vari-
ability between fetal donors for the TGF-β isoforms was very
small which is generally the opposite for that of skin from
young and old donors. Importance has been given to the
TGF-β3 isoform by a company in England, Renovo Ltd., who
have used human recombinant TGF-β3 (Juvista) in clinical
trials showing 70% response rate for scar reduction to date.
However, TGF-β1 and β2 neutralizing antibodies do not
entirely prevent scarring in the adult, and other studies ques-
tion the efficacy of TGF-β3 in wound healing [50].
More recently, inhibition of TGFbRII-mediated signaling
was demonstrated with a gene-therapy approach in a rabbit
hypertrophic scarring model showing some reduction bio-
logically. Lack of complete reduction could either be due
to the technical difficulties suggested by the authors for
low transduction efficiency, or it may suggest that factors
other than TGF-β may also be important in scarless repair.
As TGF-β’s particular importance in wound healing is also
due to their ability to modulate ECM formation, two genes
have previously been shown in wound healing in fetal skin
(laminin b1, LAMb1) and in hypertrophic scar (derma-
topontin, DPT) [51]. Dermatopontin and laminins have
important roles in cell-matrix interactions and matrix as-
sembly, and dermatopontin as been shown to be decreased in
hypertrophic scar and systemic sclerosis skin fibroblasts [52].
As wound healing is very complex, there are cer-
tainly many other molecules within the TGF-β superfamily
which could have a role. For instance, bone morphogenic
protein (BMP) family of genes and their receptors are
among those in the TGF-β superfamily genes and have
also been strongly associated with cutaneous wound healing
and scarless wound healing in the fetus. Overexpression of
BMP-6 was shown to delay re-epitheliazation and promote
scar formation in a transgenic mouse model [53]. BMP-6 is
important for maintaining skin homeostasis and is 3.8 times
higher expressed in fetal dermal fibroblasts than in new-
born foreskin fibroblasts. More recent studies have shown
evidence for the importance of angiogenesis and nerve
involvement in wound repair [54, 55]. Pleiotrophin (PTN), a
cytokine inducing heparin-binding/differentiation, is certain
to have a major role in angiogenesis in wound healing.
Midkine (MDK) and PTN, which have 50% amino acid
sequence identity and striking domain homology, are the two
members of the Ptn/Mdk developmental gene family [55].
Interestingly, PTN has been recently shown to induce func-
tional neovasculature in vivo [55]. As fetal tissue heals with
no inflammatory response, lower MDK and PTN expression
is perhaps preferable, as they could have an important role in
angiogenesis.
In the past, gene profiling differences have been shown
for fetal cells compared to adult cells [9], and therefore, it
was also of interest to determine gene expression alterations
in banked fetal dermal skin cells (used in tissue engineering
for burns and wounds to date) and young dermal skin
cells that have been banked in the same manner to have
a listing of potential gene families from fetal banked cells
to compare to young skin cells and other gene profiling
studies. Young skin was, therefore, obtained from behind
the ears of a 12 year old boy (12 yOS) following a surgical
ear alignment and with the approval of the Hospital Ethics
Committee to use this discarded material for research with
parent and child oral and written approval. To identify
differentially expressed genes in banked fetal dermal skin
cells, we used cDNA microarray containing approximately
12,500 sequences (U95A human genome chip, Affymetrix
UK, High Wycombe). Three arrays were hybridized for
banked fetal skin cells (14 wFS) and banked young skin
cells each (12 yOS). Briefly, RNA was isolated from cultured
cells at passage one for each of the three cell banks. The
statistical analyses were performed with a classical analysis of
variance (ANOVA) followed by the global error assessment
(GEA). Genes were selected by this method at α level
0.001. Significant genes, with at least a 1.5 fold change,
were classified according to the gene ontology following the
criteria of the DAVID (database for annotation, visualization,
and integrated discovery) as described previously [9].
When comparing banked fetal dermal skin cells to
banked young fibroblasts with our conditions, 167 genes
changed by 1.5 fold or more. Between those genes, 74
were upregulated in fetal cells and 93 were downregulated
(Table 1). Gene ontology of important differentially ex-
pressed genes was annotated following the criteria of the
DAVID database (http://david.abcc.ncifcrf.gov/) for annota-
tion, visualization, and integrated discovery) [56, 57]. As
many of the genes analyzed could be involved in multiple
biological processes, they have been placed in a category for
their best representation (Figure 2).
Although individual growth factors (TGF-β2, TGF-β3,
IL-10, and PDGF) have been shown in the clinic to help
in different aspects of overall wound healing, it is indeed a
very complex process [3, 45]. Most likely, many factors taken
together are necessary for complete wound closure which
could indeed be offered by a cell-based therapy for which
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Table 1: Regulated genes in fetal banked cells compared to young banked cells.
Enter gene ID Gene symbol Gene name Fold increase (expressed in log2)
3205 HOXA9 Homeobox A9 4.103
2890 GRIA1 Glutamate receptor, ionotropic, AMPA 1 4.050
3223 HOXC6 Homeobox C6 3.255
3202 HOXA5 Homeobox A5 3.243
2861 GPR37 G protein-coupled receptor 37 (Endothelin receptor
type B-LIKE)
3.221
5789 PTPRS Protein tyrosine phosphatase, receptor type, D 3.171
3206 HOXA10 Homeobox A10 3.084
2321 FLT1 FMS-related tyrosine kinase 1 3.060
9452 ITM2A Integral membrane protein 2A 3.030
862 RUNX1T1 RUNT-related transcription factor 1; translocated TO, 1
(cyclin D-related)
2.985
1047 CLGN Calmegin 2.916
744 MPPED2 Metallophosphoesterase domain containing 2 2.844
9056 SLC7A7 Solute carrier family 7, Member 7 2.806
1948 EFNB2 Ephrin-B2 2.770
23266 LPHN2 Latrophilin 2 2.714
9865 KIAA0644 KIAA0644 gene product 2.689
23705 CADM1 Immunoglobulin superfamily, member 4 2.607
1016 CDH18 Cadherin 18, type 2 2.553
2294 FOXF1 Forkhead box F1 2.543
140462 ASB9 DKFZP564L0862 protein 2.452
5947 RBP1 Retinol binding protein 1, cellular 2.394
83939 EIF2A Eukaryotic translation initiation factor 2A, 65 KDA 2.276
5918 RARRES1 Retinoic acid receptor responder (tazarotene induced) 1 2.256
3306 HSPA2 Heat shock 70 KDA protein 2 2.211
5880 RAC2 RAS-related C3 botulinum toxin substrate 2 (RHO
family, small GTP binding protein RAC2)
2.175
151230 KLHL23 Kelch-like 23 2.171
284 ANGPT1 Angiopoietin 1 2.171
2201 FBN2 Fibrillin 2 (congenital contractural arachnodactyly) 2.164
3880 KRT19 Keratin 19 2.163
57157 PHTF2 Putative homeodomain transcription factor 2 2.147
154796 AMOT Angiomotin 2.121
1012 CDH13 Cadherin 13, H-cadherin (heart) 2.086
5507 PPP1R3C Protein phosphatase 1, regulatory (inhibitor) subunit
3C
2.042
1908 EDN3 Endothelin 3 2.032
6319 SCD Stearoyl-coa desaturase (delta-9-desaturase) 2.022
5307 PITX1 Paired-like homeodomain transcription factor 1 2.008
6899 TBX1 T-box 1 1.957
5099 PCDH7 BH-protocadherin (brain-heart) 1.939
3215 HOXB5 Homeobox B5 1.880
6664 SOX11 Sry (sex determining region Y)-box 11 1.862
4004 LMO1 Lim domain only 1 (rhombotin 1) 1.830
10924 SMPDL3A Sphingomyelin phosphodiesterase, acid-like 3A 1.810
3233 HOXD4 Homeobox D4 1.810
3232 HOXD3 Homeobox D3 1.809
1305 COL13A1 Collagen, type XIII, alpha 1 1.772
444 ASPH Aspartate beta-hydroxylase 1.767
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Table 1: Continued.
Enter gene ID Gene symbol Gene name Fold increase (expressed in log2)
5781 PTPN11 Protein tyrosine phosphatase, non-receptor type 11
(noonan syndrome 1)
1.749
4908 NTF3 Neurotrophin 3 1.741
7046 TGFBR1 Transforming growth factor, beta receptor I (activin a
receptor type II-like kinase, 53 KDA)
1.722
5743 PTGS2 Prostaglandin-endoperoxide synthase 2 (prostaglandin
G/H synthase and cyclooxygenase)
1.708
23475 QPRT Quinolinate phosphoribosyltransferase 1.704
934 CD24 CD24 antigen 1.698
10773 ZBTB6 Zinc finger protein 482 1.685
2048 EPHB2 EPH receptor B2 1.624
23089 PEG10 Paternally expressed 10 1.617
26013 L3MBTL Lethal (3) malignant brain tumor L(3)MBT protein
(drosophila) homolog
1.614
3434 IFIT1 Interferon-induced protein with tetratricopeptide
repeats 1
1.613
5156 PDGFRA Platelet-derived growth factor receptor, alpha
polypeptide
1.610
382 ARF6 ADP-ribosylation factor 6 1.610
2028 ENPEP Glutamyl aminopeptidase (aminopeptidase A) 1.607
10643 IGF2BP3 Insulin-like growth factor 2 MRNA binding protein 3 1.604
8091 HMGA2 High mobility group at-hook 2 1.580
900 CCNG1 Cyclin G1 1.579
4192 MDK Midkine (neurite growth-promoting factor 2) 1.577
552889 LOC552889 Hypothetical LOC552889 1.576
540 ATP7B Atpase, CU++ transporting, beta polypeptide 1.565
2289 FKBP5 FK506 binding protein 5 1.543
4194 MDM4 MDM4, transformed 3t3 cell double minute 4 1.538
5764 PTN Pleiotrophin 1.533
8935 SKAP2 SRC family associated phosphoprotein 2 1.528
273 AMPH Amphiphysin 1.527
2799 GNS Glucosamine (N-acetyl)-6-sulfatase (sanfilippo disease
IIID)
1.519
5311 PKD2 Polycystic kidney disease 2 (autosomal dominant) 1.518
10402 ST3GAL6 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 1.501
3764 KCNJ8 Potassium inwardly-rectifying channel, subfamily J,
member 8
−1.501
6347 CCL2 Chemokine (C-C motif) ligand 2 −1.509
2030 SLC29A1 Solute carrier family 29 −1.517
2919 CXCL1 Chemokine (C-X-C MOTIF) ligand 1 −1.519
1839 HBEGF Heparin-binding EGF-like growth factor −1.522
3488 IGFBP5 Insulin-like growth factor binding protein 5 −1.539
5678 PSG9 Pregnancy specific beta-1-glycoprotein 9 −1.557
3643 INSR Insulin receptor −1.569
10974 C10ORF116 Chromosome 10 open reading frame 116 −1.580
4071 TM4SF1 Transmembrane 4 L six family member 1 −1.580
1832 DSP Desmoplakin −1.590
4487 MSX1 MSH homeobox homolog 1 −1.613
27295 PDLIM3 PDZ and LIM domain 3 −1.615
1294 COL7A1 Collagen, type VII, alpha 1 −1.617
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Table 1: Continued.
Enter gene ID Gene symbol Gene name Fold increase (expressed in log2)
182 JAG1 Jagged 1 (alagille syndrome) −1.617
22891 ZNF365 Zinc finger protein 365 −1.619
4223 MEOX2 Mesenchyme homeobox 2 −1.660
8076 MFAP5 Microfibrillar associated protein 5 −1.665
51363 GALNAC4S-6ST KIAA0598 gene product −1.676
5354 PLP1 Proteolipid protein 1 −1.694
1410 CRYAB Crystallin, alpha B −1.699
4854 NOTCH3 Notch homolog 3 −1.743
116039 OSR2 ODD-skipped related 2 −1.753
10873 ME3 Malic enzyme 3, NADP(+)-dependent, mitochondrial −1.760
5865 RAB3B RAB3B, member RAS oncogene family −1.764
10391 CORO2B Coronin, actin binding protein, 2B −1.770
22809 ATF5 Activating transcription factor 5 −1.782
6356 CCL11 Chemokine (C-C motif) ligand 11 −1.783
7869 SEMA3B Semaphorin 3B −1.802
8404 SPARCL1 SPARC-like 1 (MAST9, HEVIN) −1.813
1004 CDH6 Cadherin 6, type 2, K-cadherin (fetal kidney) −1.823
131578 LRRC15 Leucine rich repeat containing 15 −1.836
3855 KRT7 Keratin 7 −1.846
11145 HRASLS3 HRAS-like suppressor 3 −1.853
5919 RARRES2 Retinoic acid receptor responder −1.862
5493 PPL Periplakin −1.882
27063 ANKRD1 Ankyrin repeat domain 1 (cardiac muscle) −1.891
684 BST2 Bone marrow stromal cell antigen 2 −1.918
8190 MIA Melanoma inhibitory activity −1.932
7042 TGFB2 Transforming growth factor, beta 2 −1.950
6004 RGS16 Regulator of G-protein signalling 16 −1.969
7020 TFAP2A Transcription factor AP-2 alpha −2.008
3589 IL11 Interleukin 11 −2.022
8549 LGR5 Leucine-rich repeat-containing G protein-coupled
receptor 5
−2.027
2277 FIGF C-FOS induced growth factor −2.029
4958 OMD Osteomodulin −2.047
10351 ABCA8 ATP-binding cassette, sub-family A (ABC1), member 8 −2.051
2065 ERBB3 V-ERB-B2 erythroblastic leukemia viral oncogene −2.073
5649 RELN Reelin −2.130
6663 SOX10 SRY (sex determining region Y)-BOX 10 −2.172
2878 GPX3 Glutathione peroxidase 3 (plasma) −2.183
1620 DBC1 Deleted in bladder cancer 1 −2.208
4629 MYH11 Myosin, heavy polypeptide 11, smooth muscle −2.221
4046 LSP1 Lymphocyte-specific protein 1 −2.224
5730 PTGDS Prostaglandin D2 synthase 21 KDA (BRAIN) −2.252
6781 STC1 Stanniocalcin 1 −2.290
1675 CFD Complement factor D (ADIPSIN) −2.298
3490 IGFBP7 Insulin-like growth factor binding protein 7 −2.317
10439 OLFM1 Olfactomedin 1 −2.341
23090 ZNF423 Zinc finger protein 423 −2.372
1842 ECM2 Extracellular matrix protein 2 −2.426
11098 PRSS23 Protease, serine, 23 −2.431
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Table 1: Continued.
Enter gene ID Gene symbol Gene name Fold increase (expressed in log2)
7857 SCG2 SECRETOGRANIN II (CHROMOGRANIN C) −2.448
2628 GATM Glycine amidinotransferase −2.463
358 AQP1 Aquaporin 1 −2.507
8418 CMAH Cytidine monophosphate-N-acetylneuraminic acid
hydroxylase
−2.533
2006 ELN Elastin (supravalvular aortic stenosis, williams-beuren
syndrome)
−2.589
3481 IGF2 Insulin-like growth factor 2 (somatomedin A) −2.592
4804 NGFR Nerve growth factor receptor (tnfr superfamily,
member 16)
−2.625
2675 GFRA2 GDNF family receptor alpha 2 −2.646
249 ALPL Alkaline phosphatase, liver/bone/kidney −2.671
2596 GAP43 Growth associated protein 43 −2.678
11075 STMN2 Stathmin-like 2 −2.695
5803 PTPRZ1 Protein tyrosine phosphatase, receptor-type, Z
polypeptide 1
−2.695
8744 TNFSF9 Tumor necrosis factor superfamily, member 9 −2.723
8644 AKR1C3 Aldo-keto reductase family 1, member C3 −2.837
8839 WISP2 WNT1 inducible signaling pathway protein 2 −2.910
124 ADH1C Alcohol dehydrogenase 1A (CLASS I) −2.927
1734 DIO2 Deiodinase, iodothyronine, type II −2.947
1116 CHI3L1 Chitinase 3-like 1 (cartilage glycoprotein-39) −3.329
5320 PLA2G2A Phospholipase A2, group IIA (platelets, synovial fluid) −3.355
3123 HLA-DRB6 Major histocompatibility complex, class II, DR beta 1 −3.415
3128 HLA-DRB5 Major histocompatibility complex, class II, DR beta 6 −3.415
4915 NTRK2 Neurotrophic tyrosine kinase, receptor, type 2 −3.552
3479 IGF1 Insulin-like growth factor 1 (somatomedin C) −3.682
3897 L1CAM L1 cell adhesion molecule −3.706
347 APOD Apolipoprotein D −3.749
50486 G0S2 G0/G1switch 2 −3.913
2824 GPM6B Glycoprotein M6B −4.029
1299 COL9A3 Collagen, type IX, alpha 3 −4.076
9244 CRLF1 Cytokine receptor-like factor 1 −4.463
2662 GDF10 Growth differentiation factor 10 −4.813
1311 COMP Cartilage oligomeric matrix protein −4.840
many factors could be different in fetal cells such as those
found in Table 1.
Indeed, it has been shown that efficient repair could
be obtained in 2nd and 3rd degree burns in children [7],
acute wounds [8], and in chronic wounds [9] to date, and
the whole-cell bioprocessing and age of the cells were very
important aspects [10, 12].
2. Fetal Tissue Collection, Culture, and
Cell Bank Requirements
One of the major challenges for assuring that more patients
will benefit from cell-based therapies in the future will be
the optimisation of the choice of cell type as well as their
isolation and proliferation. The development of master cell
banks from the cell choice provides a major advantage
for the creation of a therapeutic biological agent. Careful
selection of donors and extensive screening of both the
donor and cultured cells avoids transmissible viral, fungal, or
bacterial disease and, therefore, can provide a safe and secure
utilization of cells for therapeutic purposes.
Fetal cells have the advantage of being an organ donation,
and only very small biopsies are necessary for developing ex-
tensive, consistent master cell banks for many tissues. Thor-
ough safety testing of mother donor for infectious diseases
(status of the donor for HIV, HBV, and HCV) at the time of
tissue donation and again 3 months after to ensure negative
sero-conversion can be ensured. During the informed con-
sent of the patient, an interview for overall health is recorded
to evaluate eligibility into an organ donation program. For
the tissue, information concerning the age of the fetus, date,
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Upregulated
Angiogenesis
Apoptosis
Cell adhesion
Cell cycle
Cell morphogenesis
Cytoskeleton
Development
Immune response
Metabolic process
Downregulated
Angiogenesis
Apoptosis
Cell adhesion
Cell cycle
Cell morphogenesis
Cytoskeleton
Development
Immune response
Metabolic process
Biological Process David∗ Category Upregulated Downregulated
Angiogenesis 4 5
Apoptosis 3 3
Cell Adhesion 8 9
Cell Cycle 3 4
Cell Morphogenesis 2 3
Cytoskeleton 1 3
Development 4 11
Immune Response 4 7
Metabolic Process 28 18
Signal Transduction 12 18
Others and Unknown 8 15
∗Nature Protocols 2009; 4(1): 44 and Genome Biology 2003; 4(5): P3.
Figure 2: Gene profiling and biological processes of fetal versus young skin cells. A cDNA microarray containing approximately 12,500
sequences (U95A human genome chip, Affymetrix UK, High Wycombe) was used to identify differentially expressed genes in banked fetal
dermal skin cells compared to young skin cells. Three arrays were hybridised for each separate cell bank, and gene ontology of important
differentially expressed genes was annotated following the criteria of the DAVID database (http://david.abcc.ncifcrf.gov/) for annotation,
visualization, and integrated discovery. Biological processes of gene ontology is reported in the pie graphs for both up- and down-regulated
genes (category for their best representation).
time, and place of acquirement need to be obtained along
with types and amounts of tissue received. The transfer
containers can be labelled with the identification code to
assure an anonymous organ donation. All culture products
used for the transfer of tissue and cell culture need to be of
clinical grade quality. Cell banking and testing criteria need
to be accomplished under cGMP conditions such as required
for human diploid cells used for vaccine production and for
cell substrates used for biotechnological products. Testing
routinely accomplished on cell banks includes tests for
viruses, virus-like particles, mycoplasmas, fungi, yeasts, and
bacteria with both in vitro and in vivo testing. Donor source
is identified by isoenzyme testing, and in vitro testing of
picornavirus, orthomyxovirus, pramyxovirus, herpesvirus,
adenovirus, and reovirus is routinely accomplished with
several control cell lines when the tissue is human source
(Q-PCR for HepB, HepC, HIV-1, HIV-2, HTLV-1, HTLV-2,
HHV-6, HHV-7, HHV-8, EBV, hCMV, SV40, and B19 par-
vovirus). In vivo virus testing using suckling mice, adult mice,
guinea pigs and embryonated eggs is routinely employed.
It is important to note that until now, there have been no
reported biopharmaceuticals derived from continuous cell
cultures that have been implicated in the transmission of
infectious agents to humans. Most sources of contamination
are adventitious, which means that the contamination is
introduced from an external source such as the culture
products.
3. Cellular Delivery Systems: CollagenMatrix,
Cream, and Hydrogel
Once safety can be assured, efficient cell presentation with
biocompatible delivery systems can be assessed for specific
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Figure 3: Cell delivery by “biological bandage”, hydrogel, and pharmaceutical cream formulation. Each identical ampoule of fetal skin cells
(working cell bank) can be seeded directly into biocompatible collagen (Tissue Fleece, Baxter, Switzerland), hydrogels (Mesolis, Anties, Plan-
les-Ouates, Switzerland), or into pharmaceutical cream formulations (oil-in-water emulsion base was prepared under GLP, Good Laboratory
Practices) that assure biological stability.
tissues. For delivery systems, biocompatible biomaterials
need to be available in order to provide an extracellular
matrix environment for cell differentiation, delivery, and
release. To be admitted for clinical use, it is more rapid to use
approved medical device quality material. Cell and materials
need to be tested together to assure not only biocompati-
bility but also their interactions, cellular stability, possible
degraded by-products of combination, and degradation or
absorption. Ease of applicability of the final product will be
of importance for clinical use.
Preparations from biologicals, and particularly from live
cells and their delivery to the patient are a major complica-
tion for treatment, and the shelf life is very limited with such
preparations. Many products for skin repair have applied
alternatives such as freeze-dried, frozen, and refrigerator
stocking [18–23]. Stability and bioequivalence will have to
meet the exigent and stringent technical aspects for develop-
ment of therapeutic products.
Cellular therapies can be delivered as three-dimensional
constructs (tissue-engineered live cell constructs) that can be
placed topically over wound and scar surfaces or in solutions
composed of creams or biogels. For large-surface wounds
and areas that are difficult to apply overlying bandages,
cream and biogel preparations permit an advantage for
multiple daily applications with either live (hydrogel) or in-
activated (cream) cells (Figure 3). Final preparations need to
be consistent with equivalent “dosage” of cellular products
delivered such as a cell density or by protein content.
4. Assessment of Fetal Cell Therapy inWound
and ScarManagement
Management of wounds using fetal cell therapy have been
intended for both acute and chronic wounds and for burns.
In the first clinical studies reported using continuous fetal
skin cell lines [7, 8], they were designed to prepare wound
beds with fetal cells before autografting of patients who
were programmed for secondary surgery for wound closure.
This fetal cell preparative step was accomplished with the
intention of having both a better “take” for the autograft and
enhanced quality of treated skin. For pediatric burn patients,
the pretreatment with fetal cells showed to be very efficient
in wound closure to the point, where all 8 patients included
in the study did not have to have the planned autografts for
continued treatment [7, 8]. Treated skin showed complete
closure rapidly with little hypertrophy of new skin and no
retraction seen.
In studies reported using fetal cells for chronic leg ulcers,
patients were selected on the basis of a history of having
refractory chronic leg ulcers, which did not heal using tra-
ditional therapies, such as compression (active and passive),
hydrocolloids, and autografts [9]. Ulcers such as illustrated
in Figure 4 (female patient 1, with a history of painful post-
thrombotic ulcer for 14 years, consecutive to deep venous
system and short saphenous vein insufficiency) portray the
use of several delivery systems of live and inactivated fetal
skin cells. For this particular patient, previous autografts and
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Figure 4: Fetal cell therapy of chronic wounds. Patient 1 (female 64 years old) with a history of painful postthrombotic ulcer for 14
years, consecutive to deep venous system, and short saphenous vein insufficiency (a). Evolution of the large, deep, and painful ulcer with
applications of fetal skin constructs one time per week at 1 month (b) and two months (c). Following the majority of closure at 2 months,
surrounding skin was treated with pharmaceutical cream preparation with inactivated fetal skin cells until full closure at 11 weeks (d). At
one year followup, the patient shows skin that is still atrophic but no presence of scar tissue. “Biological bandage” preparations: fetal cells
(seeding density of 5 × 103 cells/cm2 with cells from the WCB at passages 3-4) were placed in culture media and seeded on the collagen
sheet and placed into a 37◦C incubator at 95% relative humidity and 10% CO2. Final products were employed for the patients in clinical
Phase I and II studies for burns and wounds. Cream preparation: the cream was prepared under controlled, clean-room conditions in an
automated pharmaceutical machine (Moltomat, Krieger AG, Basel, Switzerland). Its composition contained hydrogenated vegetable oil,
glycerine, propylene glycol, cetearyl, ethyhexanoate, decyl oleate, ceteanyl alcohol, cetyl palmitate, glucose, ascorbyl palmitate, tocopheryl
acetate, propylparaben, methylparaben, potassium chloride, magnesium chloride, sodium cetearyl sulphate, and simethicone. Samples were
tested for quality control with respect to microbiological and physicochemical (viscosity, pH, conductivity, mass volume, colorimetry, and
microscopy). Cell concentrations of 5×103/mL were used on deteriorated skin of patients surrounding chronic ulcers and following wound
closure of wound burn patients (Figure 5).
different compression therapies including 4 layers bandages
were not successful. Immediately following the first fetal
skin construct, edema diminished, pain was relieved, and
fibrin production elimination was evident. Applications of
fetal skin constructs one time per week were capable of
gradual but rapid closure of this large, deep, and painful
ulcer. At 11 weeks, the larger portion of the ulcer was healed.
Healed ulcer and surrounding skin was treated with phar-
maceutical cream preparation with inactivated fetal skin
cells until full closure. At one year followup, the patient
shows skin that is still atrophic but with no presence of
scar tissue (Figure 4). Although etiologies of ulcer patients
are varied, similar observations were reported using fetal
skin cells for treatment in 8 patients representing 13 ulcers
included in the clinical safety studies [9]. Examples of rapid
evolution of acute wounds and burns treated in the same
manner with fetal cell preparations are portrayed in Figure 5.
These patients were selected to represent the early repair
processes noted and associated anti-inflammatory effects.
Regardless of wound etiology (Patient 2 presented with an
incision from a glass wound, Patient 3 with an intense
soder burn, and Patient 4 with an acid burn), it can be
generally observed that rapid epitheliazation of skin was
initiated.
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Patient 4: acid burnPatient 3: soder burnPatient 2: glass cut
Day 1
Day 2
Day 6
Follow up 3 month 3 month 1 month
Figure 5: Patients with various forms of acute wounds (Patient 2) glass incision (Patient 3) soder burn, and (Patient 4) acid burn treated
with fetal cell preparations as described for Figure 4. Evolution of wounds early in treatment with bandage changes every 2 days illustrates
rapid wound repair with low associated inflammation.
5. Discussion
Biologicals for wound and scar management have predom-
inantly been developed with neonatal or young foreskin
tissue cell culture to date (companies including, Smith and
Nephew, XCELLentis, Organogenesis, Ortec, and DFB Phar-
maceuticals) [13–15, 17, 18]. Differences of expression in
wound healing gene families between fetal cells and foreskin
cells used in biological preparations could be responsible
for more efficient repair processes seen in the clinic and
particularly for the rapidity in the treatment of acute wounds
and burns [11]. Fetal skin represents the ideal paradigm of
all tissue repair due to its inherent ability to repair through
regeneration rather than scar. Even though fetal wound
repair is a tightly regulated process involving many cellu-
lar mediators, the precise mechanisms of efficient wound
healing without scar formation remain unknown despite the
great increase in knowledge gained over the past decades.
Chen et al. [58] have proposed that understanding the
“blueprint of fetal skin repair” might allow the manipulation
of adult wound healing in order to decrease scarring and
fibrosis. There are indeed many genes that are significantly
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different in the “fetal skin blueprint” when compared to both
younger and older skin that have been elucidated in previous
work [9] and in this paper with banked fetal and young skin
cells accomplished with the same cell banking techniques.
Herein, we show that expression profiling of banked fetal
cells compared to young skin has provided biological group-
ing of important gene families implicated in the mechanism
of wound repair (such as cell adhesion, angiogenesis, and
development; see pie graphs Figure 2, Table 1).
Indeed, individual growth factors (TGF-β2, TGF-β3, IL-
10, and PDGF) have been shown in the clinic to help in
different aspects of overall wound healing, but it is a very
complex process. Most likely, many factors taken together
are necessary for complete wound closure which could
indeed be offered by a cell-based therapy for wound man-
agement. In making parallels with currently used medicines,
it is now becoming more and more of a problem for single
growth factors in wound and tissue repair. As milligram
quantities are necessary for treatment of wounds such as
that with platelet-derived growth factor (PDGF, Regranex),
the long-term use is showing some safety concern. The
use of this growth factor for the treatment of chronic leg
ulcers has now been limited to short treatment regimens due
to increased cancer in the patients (Ortho-McNeil-Janssen
Pharmaceuticals; Important Drug Warning insert of medi-
cation). When only one growth factor or cytokine is used,
the dosage accumulations are very high. Cellular therapies
(or total cellular products) could provide the more correct
balance for dosages of individual proteins or factors. The
pmol/nmol quantities of individual proteins (when delivered
all together are ∼2-3 µg) have been shown to be effective
without the secondary effects on long term [7–9].
New biologicals may be of high interest if the safety
and simplicity can be assured and if the overall cost can be
limited.
Regarding the use of the cells for preclinical trials, it will
be particularly important to ensure consistency of growth
of the cells and consistency of the harvest obtained. High
consistency in fetal cell banking can be achieved due to the
minimum requirements of fetal cell cultures. In contrast with
MSC, fetal cells do not require feeder layers for growth nor
growth factors for differentiation. Fetal cells show qualities
required for the establishment of GMP cell banks to be
used for medicinal and tissue-engineering products. The
lifespan and the proliferation rate of the fetal cells can allow
master cell banks of 100–300 ampoules containing 5–10
millions cells each from 2 cm2 of tissue at very early passaging
(Passage 1 and 2). MCB and WCB have been prepared from
fetal skin tissue in short periods of time compared to other
primary cells [8, 10].
Regulation of final products and the simplicity will
be mandatory milestones for biological development. Until
2007, Phase I and II safety studies with fetal cells were reg-
ulated in Switzerland (where the clinical trials were held) by
the Department of Public Health (OFSP) under Transplanta-
tion Law (for living cell transplants) and by “hospital prepa-
rations in small quantities” by the state chemist (for inacti-
vated cells). For comparison in the United States by the FDA,
other cell types (i.e., foreskin) were regulated, in the majority,
as medical devices or cosmetic products. New regulatory
requirements issued in recent years (2007) will assure better
safety, but cost will be largely affected. All cellular products
must be in compliance with guidelines of good manufactur-
ing practice (GMP) with respect to medicinal products and
investigational medicinal products for human use. The Euro-
pean Union (EU) regulation on advanced therapy medicinal
products (ATMPs) was adopted in all European Member
States on Dec. 30, 2008, and the FDA recently also proposed
regulations on human cells, tissues, as well as for cellular and
tissue-based products. The main scope of the regulations is to
establish clear classification criteria for many new cell-based
medicinal products. For the EU, it makes reference to the
2004/23/EC directive on donation, procurement, and testing
of human cells and tissues and also with directive 2002/98/EC
on human blood and blood components. All together, these
directives dictate that human cells have to be in compliance
with the quality requirements therein described and that
all ATMP have to be prepared under GMP conditions. Key
elements including identity, purity, sterility, stability, safety,
and efficacy are recommended for cellular-based products.
In all, these new regulations impose strict criteria for the pro-
duction and the environment used for the production of cell-
based products to be used in clinical trials and treatments
[59–69]. Evolution of advanced cellular therapeutics world-
wide and how they are regulated will have a major impact on
availability to patients. Clear regulatory affairs of cellular use,
whether they are delivered living or inactivated, will be nec-
essary to help researchers and clinicians in future therapies.
Cell therapies and tissue engineering are beginning to
show great promise in wound and scar management. The cell
choice is, therefore, an important factor for simplifying the
overall technique and bringing therapy rapidly to the patient.
Thus, fetal cells with their high expansion, simple culture
conditions (do not require feeder layers or extensive growth
factors for expansion which is a major reason for their con-
sistency in scaling out), and low immunogenicity properties
[10, 12] are ideal conditions for whole-cell bioprocessing
destined for cell therapy, tissue-engineering, and medicinal
products. Additionally, they have already been used in safety
clinical Phase I and II studies showing rapid and efficient
tissue repair with minimal scarring [7–9, 12].
Delivery systems to afford better stocking and stability
will be important milestones for biological products, and
topical preparations that show biological activity would be a
great benefit. Overall, the advantage of cellular preparations
is that there is no need for a chemical “active ingredient” for
wound healing and scar management.
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